PURPOSE: To determine whether a constitutively active protein kinase C (PKC)-alpha stimulates rat and human conjunctival goblet cell proliferation through activation of ERK 1/2. METHODS: Conjunctivas from rat and human were minced and goblet cells were allowed to grow. Goblet cells were serum starved and incubated with an adenovirus containing a constitutively active form of PKCalpha (Ad-myr-PKCalpha, 1 x 10(7) pfu), EGF (10(-7) M), or both. The location of myrPKCalpha was determined by immunofluorescence microscopy. Cultured goblet cells were preincubated with the PKC inhibitor calphostin C (10(-10)-10(-7) M) or the ERK 1/2 inhibitor U0126 (10(-9)-10(-6) M) before incubation with Ad-myr-PKCalpha. Cell proliferation was measured. RESULTS: Transduction of rat goblet cells with Ad-myr-PKCalpha did not change PKC location compared with nontransduced cells. Incubation with Ad-myr-PKCalpha caused an increase in cell proliferation by 2.5+/-0.3-fold, whereas EGF increased proliferation by 2.1+/-0.2-fold. Simultaneous addition of Ad-myr-PKCalpha and EGF did not further increase proliferation. U0126 inhibited Ad-myr-PKCalpha-stimulated proliferation a maximum of 70%. In human goblet cells, incubation with Ad-myr-PKCalpha caused an increase in cell proliferation by 2.3+/-0.3-fold, whereas EGF increased proliferation by 3.1+/-0.4-fold. Simultaneous addition of Ad-myr-PKCalpha and EGF decreased proliferation compared with either compound alone. Ad-myr-PKCalpha caused ERK 1/2 to translocate to the nucleus in rat and human cells, but the translocation was blocked by U0126. CONCLUSIONS: Activation of PKCalpha alone by inducing phosphorylation of ERK 1/2 and translocating it to the nucleus is necessary and sufficient to cause conjunctival cell proliferation in rat, and probably human, goblet cells.
PURPOSE: To determine whether a constitutively active protein kinase C (PKC)-alpha stimulates rat and human conjunctival goblet cell proliferation through activation of ERK 1/2. METHODS: Conjunctivas from rat and human were minced and goblet cells were allowed to grow. Goblet cells were serum starved and incubated with an adenovirus containing a constitutively active form of PKCalpha (Ad-myr-PKCalpha, 1 x 10(7) pfu), EGF (10(-7) M), or both. The location of myrPKCalpha was determined by immunofluorescence microscopy. Cultured goblet cells were preincubated with the PKC inhibitor calphostin C (10(-10)-10(-7) M) or the ERK 1/2 inhibitor U0126 (10(-9)-10(-6) M) before incubation with Ad-myr-PKCalpha. Cell proliferation was measured. RESULTS: Transduction of rat goblet cells with Ad-myr-PKCalpha did not change PKC location compared with nontransduced cells. Incubation with Ad-myr-PKCalpha caused an increase in cell proliferation by 2.5+/-0.3-fold, whereas EGF increased proliferation by 2.1+/-0.2-fold. Simultaneous addition of Ad-myr-PKCalpha and EGF did not further increase proliferation. U0126 inhibited Ad-myr-PKCalpha-stimulated proliferation a maximum of 70%. In human goblet cells, incubation with Ad-myr-PKCalpha caused an increase in cell proliferation by 2.3+/-0.3-fold, whereas EGF increased proliferation by 3.1+/-0.4-fold. Simultaneous addition of Ad-myr-PKCalpha and EGF decreased proliferation compared with either compound alone. Ad-myr-PKCalpha caused ERK 1/2 to translocate to the nucleus in rat and human cells, but the translocation was blocked by U0126. CONCLUSIONS: Activation of PKCalpha alone by inducing phosphorylation of ERK 1/2 and translocating it to the nucleus is necessary and sufficient to cause conjunctival cell proliferation in rat, and probably human, goblet cells.
Authors: Robin R Hodges; Isabelle Raddassi; Driss Zoukhri; Alex Toker; Andrius Kazlauskas; Darlene A Dartt Journal: Invest Ophthalmol Vis Sci Date: 2004-11 Impact factor: 4.799
Authors: H Cai; U Smola; V Wixler; I Eisenmann-Tappe; M T Diaz-Meco; J Moscat; U Rapp; G M Cooper Journal: Mol Cell Biol Date: 1997-02 Impact factor: 4.272
Authors: Marie A Shatos; Jian Gu; Robin R Hodges; Kameran Lashkari; Darlene A Dartt Journal: Invest Ophthalmol Vis Sci Date: 2008-04-17 Impact factor: 4.799
Authors: Marie A Shatos; José D Ríos; Yoshitaka Horikawa; Robin R Hodges; Eli L Chang; Carlo R Bernardino; Peter A D Rubin; Darlene A Dartt Journal: Invest Ophthalmol Vis Sci Date: 2003-06 Impact factor: 4.799
Authors: Darlene A Dartt; Robin R Hodges; Dayu Li; Marie A Shatos; Kameran Lashkari; Charles N Serhan Journal: J Immunol Date: 2011-02-28 Impact factor: 5.422
Authors: Robin R Hodges; Jeffrey A Bair; Richard B Carozza; Dayu Li; Marie A Shatos; Darlene A Dartt Journal: Exp Eye Res Date: 2012-09-04 Impact factor: 3.467
Authors: Dayu Li; Jianwei Jiao; Marie A Shatos; Robin R Hodges; Darlene A Dartt Journal: Invest Ophthalmol Vis Sci Date: 2013-04-23 Impact factor: 4.799